Open AccessThis article is
- freely available
Respiratory Syncytial Virus: Current Progress in Vaccine Development
Department of Infectious Diseases, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA
Department of Microbiology, Immunology and Biochemistry, University of Tennessee Health Science Center, 858 Madison Avenue, Memphis, TN 38163, USA
* Author to whom correspondence should be addressed.
Received: 16 January 2013; in revised form: 1 February 2013 / Accepted: 4 February 2013 / Published: 5 February 2013
Abstract: Respiratory syncytial virus (RSV) is the etiological agent for a serious lower respiratory tract disease responsible for close to 200,000 annual deaths worldwide. The first infection is generally most severe, while re-infections usually associate with a milder disease. This observation and the finding that re-infection risks are inversely associated with neutralizing antibody titers suggest that immune responses generated toward a first RSV exposure can significantly reduce morbidity and mortality throughout life. For more than half a century, researchers have endeavored to design a vaccine for RSV that can mimic or improve upon natural protective immunity without adverse events. The virus is herein described together with the hurdles that must be overcome to develop a vaccine and some current vaccine development approaches.
Keywords: respiratory syncytial virus; candidate vaccines; protective immunity
Citations to this Article
Cite This Article
MDPI and ACS Style
Rudraraju, R.; Jones, B.G.; Sealy, R.; Surman, S.L.; Hurwitz, J.L. Respiratory Syncytial Virus: Current Progress in Vaccine Development. Viruses 2013, 5, 577-594.
Rudraraju R, Jones BG, Sealy R, Surman SL, Hurwitz JL. Respiratory Syncytial Virus: Current Progress in Vaccine Development. Viruses. 2013; 5(2):577-594.
Rudraraju, Rajeev; Jones, Bart G.; Sealy, Robert; Surman, Sherri L.; Hurwitz, Julia L. 2013. "Respiratory Syncytial Virus: Current Progress in Vaccine Development." Viruses 5, no. 2: 577-594.